Brainstorm Cell Therapeutics Inc.
BCLI- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001137883
No open-market purchases or sales by Brainstorm Cell Therapeutics Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Brainstorm Cell Therapeutics Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 39
- −2 vs. Q4 2021
- Shares held
- 4.16M
- −237.2K (−5.4%) vs. Q4 2021
- Total value
- $14.0M
- −$3.61M (−20.5%) vs. Q4 2021
- New holders
- 5
- 10 more added
- Sold out
- 7
- 9 more reduced
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCLI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 5 | $1.73K |
| Q2 2025 | 34 | $264.0K |
| Q1 2025 | 32 | $1.09M |
| Q4 2024 | 34 | $560.3K |
| Q3 2024 | 38 | $2.52M |
| Q2 2024 | 48 | $4.09M |
| Q1 2024 | 47 | $2.19M |
| Q4 2023 | 46 | $1.04M |
| Q3 2023 | 53 | $928.4K |
| Q2 2023 | 57 | $11.5M |
| Q1 2023 | 48 | $20.4M |
| Q4 2022 | 43 | $6.16M |
| Q3 2022 | 42 | $17.1M |
| Q2 2022 | 48 | $11.0M |
| Q1 2022 | 39 | $14.0M |
| Q4 2021 | 42 | $17.6M |
| Q3 2021 | 52 | $16.9M |
| Q2 2021 | 57 | $21.4M |
| Q1 2021 | 75 | $32.1M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Brainstorm Cell Therapeutics Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Westside Investment Management, Inc. | 200 | $0 | 0.00% | 00.0% | Unchanged |
| Mark Sheptoff Financial Planning, LLC | 100 | $0 | 0.00% | 00.0% | Unchanged |
| First Manhattan Co | 500 | $1.00K | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 481 | $1.62K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 1,533 | $5.00K | 0.00% | 00.0% | Unchanged |
| Simplex Trading, LLC | 2,378 | $7.00K | 0.00% | +2,178+1,089.0% | Added |
| Washington Trust Co | 2,500 | $8.00K | 0.00% | 00.0% | Unchanged |
| Institutional & Family Asset Management, LLC | 3,000 | $10.0K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 7,222 | $24.0K | 0.00% | +4,130+133.6% | Added |
| UBS Group AG | 7,706 | $26.0K | 0.00% | −6,701−46.5% | Reduced |
| Steward Partners Investment Advisory, LLC | 7,700 | $26.0K | 0.00% | −2,000−20.6% | Reduced |
| Two Sigma Advisers, LP | 11,000 | $37.0K | 0.00% | −600−5.2% | Reduced |
| Charles Schwab Investment Management Inc | 11,287 | $38.0K | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Services Advisors, Inc. | 12,031 | $40.0K | 0.00% | 00.0% | Unchanged |
| CFO4Life Group, LLC | 12,000 | $40.0K | 0.01% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 12,250 | $41.0K | 0.00% | 00.0% | Unchanged |
| Aptus Capital Advisors, LLC | 12,500 | $42.0K | 0.00% | 00.0% | Unchanged |
| S.C. Financial Services, Inc. | 15,285 | $51.0K | 0.07% | 00.0% | Unchanged |
| Wells Fargo & Company | 16,225 | $55.0K | 0.00% | −2,333−12.6% | Reduced |
| Citadel Advisors LLC | 24,119 | $81.0K | 0.00% | +24,119 | New |
| Boothbay Fund Management, LLC | 29,186 | $98.0K | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 19,850 | $104.0K | 0.00% | +19,850 | New |
| Jmac Enterprises LLC | 45,430 | $153.0K | 0.04% | +45,430 | New |
| Morgan Stanley | 49,106 | $164.0K | 0.00% | −2,554−4.9% | Reduced |
| Group One Trading, L.P. | 49,097 | $165.0K | 0.00% | +49,097 | New |
| Northern Trust Corp | 55,916 | $188.0K | 0.00% | −3,175−5.4% | Reduced |
| Price T Rowe Associates Inc | 93,000 | $312.0K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 94,600 | $318.0K | 0.00% | +94,600 | New |
| State Street Corp | 96,060 | $323.0K | 0.00% | +9,357+10.8% | Added |
| Weaver Consulting Group | 130,000 | $437.0K | 0.21% | −25,500−16.4% | Reduced |
| Millennium Management LLC | 141,253 | $475.0K | 0.00% | −8,913−5.9% | Reduced |
| Raymond James & Associates | 190,403 | $640.0K | 0.00% | +900+0.5% | Added |
| JPMorgan Chase & Co | 246,202 | $827.0K | 0.00% | +53,036+27.5% | Added |
| Abner Herrman & Brock LLC | 265,000 | $890.0K | 0.12% | +32,000+13.7% | Added |
| Geode Capital Management, LLC | 283,485 | $952.0K | 0.00% | +5,384+1.9% | Added |
| Ikarian Capital, LLC | 304,161 | $1.02M | 0.31% | +14,611+5.0% | Added |
| BlackRock Inc. | 474,510 | $1.59M | 0.00% | +2,034+0.4% | Added |
| Vanguard Group Inc | 1,421,099 | $4.78M | 0.00% | −9,473−0.7% | Reduced |
| Advisor Group Holdings, Inc. | 10,839 | – | – | +719+7.1% | Added |
| Sabby Management, LLC | 0 | $0 | 0.00% | −513,211−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −10,100−100.0% | Sold out |
| Bank Julius Baer & Co. Ltd, Zurich | 0 | $0 | 0.00% | −4,167−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −3,442−100.0% | Sold out |
| Cypress Capital Management LLC (WY) | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| Aquatic Capital Management LLC | 0 | $0 | 0.00% | −800−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −133−100.0% | Sold out |
| Harbour Investments, Inc. | – | – | – | – | Not filed |